Literature DB >> 7675852

Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to delta 9-tetrahydrocannabinol.

J Romero1, L García, J J Fernández-Ruiz, M Cebeira, J A Ramos.   

Abstract

A brain constituent, the N-amide derivative of arachidonic acid, termed anandamide, has been recently proposed as a possible endogenous ligand for the cannabinoid receptor. The present study has been designed to examine whether the acute or chronic exposure to anandamide affected the binding of cannabinoid receptors in specific brain areas as occurred with the exogenous cannabinoid agonist, delta 9-tetrahydrocannabinol (THC). To this end, we measured the maximum binding capacity (Bmax) and the affinity (Kd) of cannabinoid receptors, by using [3H]CP-55,940 binding assays, in membranes obtained from several brain areas of male rats acutely or chronically treated with anandamide or THC. Results were as follows. The acute administration of either anandamide or THC increased the Bmax of cannabinoid receptors in the cerebellum and, particularly, in the hippocampus. This effect was also observed after 5 days of a daily exposure to either anandamide or THC. However, whereas the increase in the Bmax after the acute treatment seems to be caused by changes in the receptor affinity (high Kd), the increase after the chronic exposure may be attributed to an increase in the density of receptors. On the contrary, the [3H]CP-55,940 binding to cannabinoid receptors in the striatum, the limbic forebrain, the mesencephalon, and the medial basal hypothalamus was not altered after the acute exposure to anandamide or THC. However, the chronic exposure to THC significantly decreased the Bmax of these receptors in the striatum and nonsignificantly in the mesencephalon. This effect was not elicited after the chronic exposure to anandamide and was not accompanied by changes in the Kd.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7675852     DOI: 10.1016/0091-3057(95)00023-p

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  23 in total

1.  Comparative effects of pulmonary and parenteral Δ⁹-tetrahydrocannabinol exposure on extinction of opiate-induced conditioned aversion in rats.

Authors:  Laurie A Manwell; Paul E Mallet
Journal:  Psychopharmacology (Berl)       Date:  2014-11-15       Impact factor: 4.530

2.  Effects of alcohol and combined marijuana and alcohol use during adolescence on hippocampal volume and asymmetry.

Authors:  Krista Lisdahl Medina; Alecia D Schweinsburg; Mairav Cohen-Zion; Bonnie J Nagel; Susan F Tapert
Journal:  Neurotoxicol Teratol       Date:  2006-12-12       Impact factor: 3.763

3.  Neuropsychological functioning in adolescent marijuana users: subtle deficits detectable after a month of abstinence.

Authors:  Krista Lisdahl Medina; Karen L Hanson; Alecia D Schweinsburg; Mairav Cohen-Zion; Bonnie J Nagel; Susan F Tapert
Journal:  J Int Neuropsychol Soc       Date:  2007-09       Impact factor: 2.892

Review 4.  Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.

Authors:  Antonia Serrano; Loren H Parsons
Journal:  Pharmacol Ther       Date:  2011-07-18       Impact factor: 12.310

Review 5.  Weighing the Evidence: A Systematic Review on Long-Term Neurocognitive Effects of Cannabis Use in Abstinent Adolescents and Adults.

Authors:  Florian Ganzer; Sonja Bröning; Stefanie Kraft; Peter-Michael Sack; Rainer Thomasius
Journal:  Neuropsychol Rev       Date:  2016-04-28       Impact factor: 7.444

6.  FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration.

Authors:  Katherine W Falenski; Andrew J Thorpe; Joel E Schlosburg; Benjamin F Cravatt; Rehab A Abdullah; Tricia H Smith; Dana E Selley; Aron H Lichtman; Laura J Sim-Selley
Journal:  Neuropsychopharmacology       Date:  2010-03-31       Impact factor: 7.853

7.  Reduced Brain Cannabinoid Receptor Availability in Schizophrenia.

Authors:  Mohini Ranganathan; Jose Cortes-Briones; Rajiv Radhakrishnan; Halle Thurnauer; Beata Planeta; Patrick Skosnik; Hong Gao; David Labaree; Alexander Neumeister; Brian Pittman; Toral Surti; Yiyun Huang; Richard E Carson; Deepak Cyril D'Souza
Journal:  Biol Psychiatry       Date:  2015-08-29       Impact factor: 13.382

8.  Small animal PET imaging of the type 1 cannabinoid receptor in a rodent model for anorexia nervosa.

Authors:  Cindy Casteels; Nathalie Gérard; Kris van Kuyck; Lies Pottel; Bart Nuttin; Guy Bormans; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-09-05       Impact factor: 9.236

9.  Influence of chronic nicotine administration on cerebral type 1 cannabinoid receptor binding: an in vivo micro-PET study in the rat using [18F]MK-9470.

Authors:  Nathalie Gérard; Jenny Ceccarini; Guy Bormans; Bert Vanbilloen; Cindy Casteels; Karolien Goffin; Barbara Bosier; Didier M Lambert; Koen Van Laere
Journal:  J Mol Neurosci       Date:  2010-02-25       Impact factor: 3.444

Review 10.  Activation of G-proteins in brain by endogenous and exogenous cannabinoids.

Authors:  Steven R Childers
Journal:  AAPS J       Date:  2006-03-10       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.